Founded in 2023, Allink Biotherapeutics transcends traditional treatment limitations through breakthrough bispecific antibodies and ADC therapeutics. Our interdisciplinary teams unite rigorous scientific methodology with unwavering patient-centered purpose, transforming complex clinical challenges into hope-inspiring therapeutic solutions.
Our Technology Platforms and Pipeline
• Bispecific Antibody Platform — Exploring new frontiers in precision-targeted therapy through collaborative innovation
• ADC Technology Platform — Engineering high DAR, enhanced hydrophilicity and diverse configurations for next-generation ADC
• Diversified Pipeline — Building First-in-Class and Best-in-Class candidates across oncology and immune diseases
Our commitment to translating scientific potential into clinical impact is demonstrated through two ADC programs advancing to global Phase I trials - a pivotal milestone where collaborative excellence meets meaningful patient care. Multiple early-stage programs have achieved pipeline candidacy, establishing our foundation for sustained therapeutic development and global impact.
Headquartered in Shanghai's Pudong New Area (4560 Jinke Road), we operate with worldwide perspective while remaining rooted in collaborative scientific discovery.
Allink was established in 2023
Over 5 patents covering products and technology
Nearly 30 years of experience in biopharmaceutical and ADC R&D
More than 10 innovative pipelines
Experienced R&D team
Efficient execution
Proprietary platform
International collaboration experience
AllinkBio's leadership team brings over 20 years of extensive expertise in innovative drug development and corporate growth
Hui FENG Ph.D.
Founder / CEO
Dr. Feng brings nearly two decades of distinguished leadership in biopharmaceutical development and portfolio strategy. His career is defined by breakthrough achievements, including leading the development of China's first overseas -approved PD-1 monoclonal antibody (Toripalimab). During the COVID-19 pandemic, he spearheaded collaborative development of a neutralizing antibody that achieved emergency use authorization across 17 countries, directly contributing to global pandemic response efforts
Kehua FAN EMBA
Co-founder / COO
Dr. Fan brings nearly two decades of expertise in global business development and clinical development within pharmaceutical industry.She has closed over 15 multinational licensing deals in her career, including the landmark out - licensing of a COVID-19 neutralizing antibody to Eli Lilly that generated $425+ million in revenue. Her strategic leadership in international partnerships consistently accelerates drug development while maximizing both scientific innovation and commercial value creation
Li LI Ph.D.
Co-founder / Head of Research
Dr. Li has over a decade of specialized expertise in bispecific antibody (BsAb) and antibody-drug conjugate (ADC) development ,currently leading early-stage program research. He has led and participated in 5 innovative therapeutic programs supported by NSFC funding ,filed over 10 patent applications for novel therapeutic antibodies. Dr. Li played a critical role in the preclinical development of Etesevimab, a COVID-19 neutralizing antibody that received global emergency use authorization
Xiaolin WANG
Head of Clinical Research
Xiaolin is a seasoned clinical development leader with over 18 years of comprehensive experience spanning oncology, immunology, respiratory diseases, and multiple therapeutic area.She brings extensive expertise in clinical development that accelerate therapeutic development from early-phase studies through regulatory approval. She has successfully led more than 15 clinical trials across global markets, demonstrating exceptional expertise in managing complex, multi-site international studies.
Jun WANG.Ph.D.
Head of ADC Platform Development
Dr. Wang delivers over two decades of distinguished leadership in biologics research and antibody-drug conjugate (ADC) development.He earned his Ph.D. in Chemistry from Columbia University and currently overseeing ADC and small molecule platform development. Dr. Wang has demonstrated exceptional expertise in advancing therapeutic candidates from research through clinical stages. His strategic leadership has been instrumental in establishing technology platforms and research team management.
Echo Chen, ACCA
Head of Finance
With over two decades of financial and operational leadership in the pharmaceutical industry, Echo brings comprehensive expertise from senior roles at multiple MNCs and large pharmaceutical companies. Her strategic leadership encompasses establishing robust financial controls and compliance frameworks, driving operational process innovations, and delivering data-driven business insights that consistently enhance investment effectiveness and operational efficiency, enabling scalable enterprise development.
Through continuous scientific innovation, we are committed to developing world-class bispecific antibodies and ADC drugs to address unmet medical needs globally
To innovate and develop cutting-edge products that enhance human health and well-being, while adhering to the highest standards of scientific excellence.
Innovation-driven, patient-centered and proactively collaborative.
